Skip to main content

68th Annual Scientific Meeting Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Red Recording

Sig Meeting

15 Views

Therapeutics (Industry)

(T 34) The human pharmacokinetics of elismetrep, a TRPM8 migraine-associated channel blocker (MACB), are well-suited for a migraine therapeutic

Presenting Author(s)

MC

Michael F. Crutchlow, MD

VP Translational Medicine
Kallyope, Inc.
New York, NY, United States

Non-presenting Author(s)

RS

Robert Saklatvala, B.S.

VP, Pharmaceutical Sciences
Kallyope, Inc., United States
DB

Daniel Boisvert, M.A.

Senior Director, Clinical Operations
Kallyope, Inc., United States
JL

Jiajun Liu, Ph.D.

VP, Biometrics
Kallyope, Inc., United States
BL

Brett Lauring, MD, PhD

Chief Medical Officer
Kallyope, Inc.
New York, NY, United States